We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




CT Reveals COVID-19 Alters Gray-Matter Volume

By MedImaging International staff writers
Posted on 31 May 2021
Print article
Image: Subplots of GMV in superior/medial/middle frontal gyri (Photo courtesy of Georgia Institute of Technology)
Image: Subplots of GMV in superior/medial/middle frontal gyri (Photo courtesy of Georgia Institute of Technology)
A new computed tomography (CT) study reveals that some COVID-19 patients have reduced gray-matter volume (GMV) in the frontal-temporal lobe of the brain.

Researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA), Georgia State University (Atlanta, USA), the University of Brescia (Italy), and other institutions conducted a retrospective study that used source-based morphometry (SBM) analysis of CT scans in 120 neurological patients (58 patients with COVID-19 and 62 patients without, matched for age, gender, and diseases) to identify GMV changes underlying COVID-19 infection. Patients' disability levels were assessed with the six-point modified Rankin scale, at preadmission, discharge, and six-month follow-up.

The results showed lower GMV in superior/medial/middle frontal gyri that was significantly associated with a higher level of disability at both discharge and at six months follow-up, even when controlling for cerebrovascular diseases (CVD). GMV in the frontal gyri was significantly reduced in patients receiving oxygen therapy and in patients with agitation, compared to patients not receiving oxygen therapy. Patients with fever also presented significant GMV reduction in inferior/middle temporal gyri and the fusiform gyrus compared to patients without fever.

Conversely, patients with COVID-19 showed no significant GMV differences when compared to patients without COVID-19 in any brain region. According to the researchers, this suggests that COVID-19 may affect the frontal-temporal network in a secondary manner through fever or lack of oxygen, and that the gray-matter changes in the frontal region may also underlie the mood disturbances commonly exhibited by COVID-19 patients. The study was published on May 11, 2021, in Neurobiology of Stress.

“People with higher levels of disability at discharge from the hospital and six months later had reduced gray-matter volume in the superior, medial, and middle frontal gyri,” said lead author Kuaikuai Duan, PhD, of Georgia Tech, and colleagues. “Science has shown that the brain's structure affects its function, and abnormal brain imaging has emerged as a major feature of COVID-19. The frontal-temporal network could potentially be employed as a biomarker for prognosis and evaluation of treatment of COVID-19.”

Grey matter is an important component of the central nervous system (CNS), consisting of neuron cells, dendrites, unmyelinated axons, glial cells (such as astrocytes and oligodendrocytes), synapses, and capillaries. It is distinguished from white matter in that it contains numerous cell bodies and relatively few myelinated axons, while white matter contains relatively few cell bodies and is composed chiefly of long-range myelinated axons. The color difference arises mainly from the whiteness of myelin.

Related Links:
Georgia Institute of Technology
Georgia State University
University of Brescia


40/80-Slice CT System
uCT 528
Mobile Cath Lab
Photon F65/F80
New
Medical Radiographic X-Ray Machine
TR30N HF
Portable Color Doppler Ultrasound Scanner
DCU10

Print article

Channels

MRI

view channel
Image: The AI tool can help interpret and assess how well treatments are working for MS patients (Photo courtesy of Shutterstock)

AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans

Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.